Background Pericardial masses are rare disease requiring incremental diagnostic workout to differentiate benignant from malignant lesions. No solid evidence exists regarding their management, and their treatment requires a case-by-case evaluation. Case summary A 54-year-old man was diagnosed with a pericardial mass. After performing cardiac magnetic resonance and computed tomography, a high suspicion of malignancy was raised. Positron emission tomography and pericardial biopsy confirmed the presence of a primary histiocytic sarcoma. After multidisciplinary evaluation, the mass was considered not suitable for surgical removal, and a neoadjuvant chemotherapy strategy was started. The first chemotherapy regimen—consisting of cyclophosphamide, doxorubicin, etoposide, vincristine, and methylprednisolone—was not effective. Therefore, a second, more aggressive, regimen consisting of cladribine, cytarabine, granulocyte-colony stimulating factor, and mitoxantrone was started. Following the first cycle, the patient developed bone marrow aplasia and septic shock leading to the exitus. Discussion Histiocytic sarcomas primarily involving the heart are extremely rare. Surgical excision represents the first therapeutic choice when feasible. When not pursuable, a neoadjuvant therapy is preferred, although no consensus exists regarding the chemotherapy regimen.
A case report of histiocytic sarcoma mimicking acute pericarditis
Corianò, Mattia
;
2025
Abstract
Background Pericardial masses are rare disease requiring incremental diagnostic workout to differentiate benignant from malignant lesions. No solid evidence exists regarding their management, and their treatment requires a case-by-case evaluation. Case summary A 54-year-old man was diagnosed with a pericardial mass. After performing cardiac magnetic resonance and computed tomography, a high suspicion of malignancy was raised. Positron emission tomography and pericardial biopsy confirmed the presence of a primary histiocytic sarcoma. After multidisciplinary evaluation, the mass was considered not suitable for surgical removal, and a neoadjuvant chemotherapy strategy was started. The first chemotherapy regimen—consisting of cyclophosphamide, doxorubicin, etoposide, vincristine, and methylprednisolone—was not effective. Therefore, a second, more aggressive, regimen consisting of cladribine, cytarabine, granulocyte-colony stimulating factor, and mitoxantrone was started. Following the first cycle, the patient developed bone marrow aplasia and septic shock leading to the exitus. Discussion Histiocytic sarcomas primarily involving the heart are extremely rare. Surgical excision represents the first therapeutic choice when feasible. When not pursuable, a neoadjuvant therapy is preferred, although no consensus exists regarding the chemotherapy regimen.| File | Dimensione | Formato | |
|---|---|---|---|
|
ytaf594.pdf
accesso aperto
Tipologia:
Published (Publisher's Version of Record)
Licenza:
Creative commons
Dimensione
574.43 kB
Formato
Adobe PDF
|
574.43 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.




